Benefit of Temozolomide Compared to Procarbazine in Treatment of Glioblastoma Multiforme at First Relapse: Effect on Neurological Functioning, Performance Status, and Health Related Quality of Life

References

• American Cancer Society (ACS homepage), http://www.cancer.org/statistics/cff99data/html (accessed on October 5, 1999).
   Google Scholar
• Cancer Rates and Risks, 4th Ed.; Harras, E., Ed.; U.S. Department of Health and Human Services, Public Health Service, NIH, National Cancer Institute: Bethesda, MD, 1996.
   Google Scholar
• Levin, V.; Leibel, S.; Gutin, P. Neoplasms of the central nervous system. In Cancer: Principles and Practice of Oncology, 5th Ed.; DeVita, V T.J., Hellman, S., Rosenberg, S A., Eds.; Lippincott-Raven: Philadelphia, 1997; 2022–2082.
   Google Scholar
• Meyers, C A.; Grous, J J.; Ford, K M. Multifaceted models for assessing quality of life in brain cancer therapy trials. Drug Inf. J. 1996, 30, 856–857. (abstract).
   Google Scholar
• Karnofsky, D A.; Abelman, W H.; Craver, L F.; Burchenal, J H. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948, 1, 634–656.
   Web of Science ®Google Scholar
• Bowling, A. Measuring Health: a Review of Quality of Life Measurement Scales; Keynes, M., Ed.; Open University Press: Philadelphia, 1993.
   Google Scholar
• Leighton, C.; Fisher, B.; Bauman, G.; Depiero, S.; Stitt, L.; MacDonald, D.; Cairncross, G. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J. Clin. Oncol. 1997, 15 (4), 1294–1301. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Shinoda, J.; Sakai, N.; Nakatani, K.; Funakoshi, T. Prognostic factors in supratentorial WHO grade II astrocytoma in adults. Br. J. Neurosurg. 1998, 12 (4), 318–324. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bauman, G.; Lote, K.; Larson, D.; Stalpers, L.; Leighton, C.; Fisher, B.; Wara, W.; MacDonald, D.; Stitt, L.; Cairncross, J G. Pre-treatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int. J. Radiat. Oncol. Biol. Phys. 1999, 45 (4), 923–929. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Iwabuchi, S.; Bishara, S.; Herbison, P.; Erasmus, A.; Samejima, H. Prognostic factors for supratentorial low-grade astrocytomas in adults. Neurol. Med.-Chir. (Tokyo) 1999, 39 (4), 273–279. [CSA]
   PubMed Web of Science ®Google Scholar
• Allam, A.; Radwi, A.; El Weshi, A.; Hassounah, M. Oligodendroglioma: an analysis of prognostic factors and treatment results. Am. J. Clin. Oncol. 2000, 23 (2), 170–175. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nakamura, M.; Konishi, N.; Tsunoda, S.; Nakase, H.; Tsuzuki, T.; Aoki, H.; Sakitani, H.; Inui, T.; Sakaki, T. Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology 2000, 58 (2), 108–116. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nieder, C.; Nestle, U.; Motaref, B.; Walter, K.; Niewald, M.; Schnabel, K. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? Int. J. Radiat. Oncol. Biol. Phys. 2000, 46 (2), 297–302. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lagerwaard, F J.; Levendag, P C.; Nowak, P J.; Eijkenboom, W M.; Hanssens, P E.; Schmitz, P I. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int. J. Radiat. Oncol. Biol. Phys. 1999, 43 (4), 795–803. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kiebert, G M. Quality of life as an outcome in EORTC clinical trials. Eur. J. Cancer 1997, 33 (Suppl 4), S31–S34. [CROSSREF]
   PubMedGoogle Scholar
• Osoba, D.; Aaronson, N K.; Muller, M.; Sneeuw, K.; Hsu, M A.; Yung, W K.; Brada, M.; Newlands, E. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J. Neuro-oncol. 1997, 34 (3), 263–278. [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kiebert, G M.; Curran, D.; Aaronson, N K.; Bolla, M.; Menten, J.; Rutten, E H.J.M.; Nordman, E.; Silvestre, M E.; Pierart, M.; Karim, A B.M.F. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). Eur. J. Cancer 1998, 34 (12), 1902–1909. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Newlands, E S.; Blackledge, G R.; Slack, J A.; Rustin, G J.; Smith, D B.; Stuart, N S.; Quarterman, C P.; Hoffman, R.; Stevens, M F.; Brampton, M H. Phase I trial of temozolomide. Br. J. Cancer 1992, 65 (2), 287–291. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• O'Reilly, S M.; Newlands, E S.; Glaser, M G.; Brampto, M.; Rice-Edwards, J M.; Illingworth, R D.; Richards, P G.; Kennard, C.; Colquhoun, I R.; Lewis, P. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer 1993, 29A (7), 940–942. [published erratum appears in Eur. J. Cancer 1993, 29A (10), 1500]. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bleehen, N M.; Newlands, E S.; Lee, S M.; Thatcher, N.; Selby, P.; Calvert, A H.; Rustin, G J.; Brampton, M.; Stevens, M F. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 1995, 13 (4), 910–913. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Newlands, E S.; O'Reilly, S M.; Glaser, M G.; Bower, M.; Evans, H.; Brock, C.; Brampton, M H.; Colquhoun, I.; Lewis, P.; Rice-Edwards, J M.; Illingworth, R D.; Richards, P G. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer 1996, 32A (13), 2236–2241. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bower, M.; Newlands, E S.; Bleehen, N M.; Brada, M.; Begent, R J.; Calvert, H.; Colquhoun, I.; Lewis, P.; Brampton, M H. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol. 1997, 40 (6), 484–488. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yung, W K.A.; Albright, R E.; Olson, J.; Fredericks, R.; Fink, K.; Prados, M D.; Brada, M.; Bruner, J.; Yue, J.; Osoba, D.; Zaknoen, S.; Levin, V A. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 2000, 83 (5), 588–593. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Aaronson, N K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N J.; Filiberti, A.; Flechtner, H.; Fleishman, S B.; de Haes, J C. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993, 85 (5), 365–376. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Osoba, D.; Aaronson, N K.; Muller, M.; Sneeuw, K.; Hsu, M A.; Yung, W K.; Brada, M.; Newlands, E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual. Life Res. 1996, 5 (1), 139–150. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Niezgoda, H E.; Pater, J L. A validation study of the domains of the core EORTC quality of life questionnaire. Qual. Life Res. 1993, 2 (5), 319–325. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ringdal, G I.; Ringdal, K. Testing the EORTC quality of life questionnaire on cancer patients with heterogeneous diagnoses. Qual. Life Res. 1993, 2 (2), 129–140. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Osoba, D.; Zee, B.; Pater, J.; Warr, D.; Kaizer, L.; Latreille, J. Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual. Life Res. 1994, 3 (5), 353–364. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Osoba, D.; Brada, M.; Yung, W K.A.; Prados, M. Health related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 2000, 18 (7), 1481–1491. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Levin, V A. Chemotherapy of primary brain tumors. Neurol. Clin. North Am. 1985, 3 (4), 855–866.
   PubMed Web of Science ®Google Scholar
• Gelber, R D.; Goldhirsch, A. Methods for assessing treatment efficacy in trials for adjuvant therapy for breast cancer. Recent Results Cancer Res. 1989, 115, 211–219. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Scott, C. Quality-adjusted survival analysis of malignant glioma patients. Control. Clin. Trials 1997, 18 (4), 277–285. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar